Search
Displaying 521–530 of 684 for “retinal diseases”
-
Encouraging Early Report for Three Patients in LCA1-GUCY2D Gene Therapy Clinical Trial
Research NewsDevelopment of the emerging gene therapy is being funded by the Foundation’s RD Fund
-
Beacon Stories My Retina Tracker Patient Stories
Susan, who has retinitis pigmentosa, went through many tests in search of learning more about her eye disease. Once she enrolled in the My Retina Tracker® (MRT) testing program, Susan was provided with comprehensive results and a clear diagnosis, giving her clarity and hope.
-
Research News
Eye Bonds provide the opportunity to advance, and accelerate development for, more promising treatments into and through clinical trials and out to the people who need them.
-
About Page
Roster of the Foundation Fighting Blindness Scientific Advisory Board
-
Our corporate partnerships provide companies and foundations with an opportunity to engage their customers, clients and employees to help raise funds, so we can accelerate the research that will provide preventions, treatments and cures for blinding diseases.
-
Research News
Applied Genetic Technologies Corporation (AGTC), a leading developer of gene therapies, has reported the six-month follow-up data in all patients treated with its gene therapy for X-linked retinoschisis (XLRS) in its Phase I/II clinical trial.
-
Beacon Stories
Kai Wang was 18 months old when he was diagnosed with the condition. His parents never imagined the extraordinary journey they would take with their son when they learned he had a condition that would render him blind.
-
FFB Congratulates RPE65 Gene Therapy Researchers for Champalimaud Award
Research NewsOn September 4, 2018, seven researchers, including six previously funded by the Foundation, were recognized with the prestigious 2018 Antonio Champalimaud Vision Award for their contributions to the advancement of blindness-reversing RPE65 gene therapies.
-
Vision Improvements Reported in Early Stem Cell Trial for Wet AMD
Research NewsTwo patients with advanced wet age-related macular degeneration (AMD) in a Phase I clinical trial demonstrated improved visual acuity sustained for one year after a sheet of retinal pigment epithelial (RPE) cells derived from embryonic stem cells was transplanted under their retinas. Each patient had one eye treated. Vision improvement for one patient was 29 letters or about 6 lines on an eye chart. The other had a gain of 21 letters or about 4 lines.
-
Choroideremia Gene Therapy Moves into Phase 3 Human Study
Research NewsNightstar Therapeutics, a retinal-disease, gene-therapy development company in the UK, is advancing its emerging gene therapy for choroideremia into a Phase 3 clinical trial known as STAR. The study will enroll approximately 140 patients at 18 clinical sites in the US, Europe, Canada, and South America.
